We discuss the results of clinical trials studying  the use of faricimab in the treatment of retinal venous occlusion with Dr. Ramin Tadayoni, Professor of Ophthalmology University of Paris.

We review the one year results of a clinical trial using high dose aflibercept (8mg) for the treatment of diabetic macular edema with Dr. David Boyer, Adjunct Clinical Professor of Ophthalmology, USC Roski Eye Institute

We the discuss the use of wide field OCT angiography in the management of diabetic retinopathy, retinal vein occlusion, and pediatric retinal disease with Dr. Amir Kashani, Associate Professor of Ophthalmology, Wilmer Eye Institute, Johns Hopkins School of Medicine

We review the use of anti-VEGF therapy for retinopathy of prematurity and in particular, the results of a clinical trial employing aflibercept with Dr. Darius Moshfeghi, Professor of Ophthalmology, Director of the Retina Service, Byers Eye Institute, Stanford University School of Medicine.

We discuss the use of home OCT and artificial intelligence in the management of anti-VEGF therapy of neovascular AMD with Dr. Anat Loewenstein, Director, Department of Ophthalmology, Tel Aviv Medical Center, Israel.

We discuss the use of suprachoroidal triamcinolone for the treatment of macular edema with Dr. Steven Yeh, Truhlsen Chair of Ophthalmology, University of Nebraska School of Medicine.

We discuss the use of the port delivery system for the treatment of diabetic macular edema with Dr. Arshad Khanani, Director of Clinical Research, Sierra Eye Associates, Associate Clinical Professor, University of Nevada School of Medicine, Reno.

We discuss the suprachoroidal delivery of a tyrosinase kinase inhibitor and a gene therapy agent for the treatment of neovascular AMD with Dr. Mark Barakat, Assistant Clinical Professor of Ophthalmology, University of Arizona School of Medicine-Phoenix.

We discuss the use of microperimetry to assess treatment effects of anti-complement therapy (Apellis) of geographic atrophy with Dr. Nadia Waheed, Associate Professor of Ophthalmology, New England Eye Center, Tufts University School of Medicine.

We discuss the results of the RGX-314 study of subretinal gene therapy for neovascular AMD with Dr. Allen Ho, Professor of Ophthalmology, Wills Eye Hospital.